NovoPedics

Executive Summary

NovoPedics, founded in 2015 and based in San Diego, is a private medical device company focused on regenerative orthopedics. Its lead product, MeniscoFix™, is a bioresorbable polymer fiber-reinforced scaffold designed for total meniscus replacement, addressing a significant unmet need in knee cartilage repair. Unlike partial meniscectomy or allograft transplants, MeniscoFix aims to provide a synthetic, off-the-shelf solution that promotes tissue ingrowth and restores joint function. The scaffold is engineered to degrade over time, being replaced by native tissue, potentially reducing the risk of osteoarthritis progression. The company has not yet disclosed clinical trial data or regulatory submissions, but the technology represents an innovative approach to meniscal regeneration, with preclinical studies suggesting biocompatibility and mechanical resilience. NovoPedics operates in the competitive landscape of orthopedic biologics and medical devices, targeting a market size exceeding $1 billion annually for meniscus repair procedures.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) Clearance or Breakthrough Device Designation50% success
• Q4 2026Initiation of First-in-Human Clinical Trial70% success
• TBDStrategic Partnership with Major Orthopedic Company40% success